Advertisement

The European Study Group for Pancreatic Cancer (ESPAC) Trials

  • Paula GhanehEmail author
  • Khaled Dajani
  • Michael G. T. Raraty
  • Robert Suttton
  • John P. Neoptolemos
Chapter

Abstract

Pancreatic cancer is one of the most lethal malignancies with recent data quoting a worldwide annual incidence of 232,306 cases, resulting in 227,023 deaths (http://www-dep.iarc.fr/). In spite of the recent advances in the understanding of the biology, refined imaging systems, and improving surgical outcomes of pancreatic cancer, the overall 5-year survival for pancreatic cancer remains poor at less than 5% (Cress et al. 2006; Bramhall et al. 1995).

Surgical resection remains the only potentially curative intervention. Due to late presentation, however, curative resections can be offered to only 10-15% of patients with pancreatic cancer (Alexakis et al. 2004) and confer only a median survival of 12-15 months (Shaib et al. 2007; Wagner et al. 2004). The aggressive biology of pancreatic cancer dictates that even following resection, the majority of patients experience tumor recurrence either locally or through distant metastases.

Keywords

Pancreatic Cancer Adjuvant Chemotherapy Adjuvant Therapy Pancreatic Ductal Adenocarcinoma Folinic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP (2004) Current standards of surgery for pancreatic cancer. Br J Surg 91(11):1410-1427PubMedCrossRefGoogle Scholar
  2. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B (1993) Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29A(5):698-703PubMedCrossRefGoogle Scholar
  3. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP (1995) Treatment and survival in 13, 560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82(1):111-115PubMedCrossRefGoogle Scholar
  4. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403-2413PubMedGoogle Scholar
  5. Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JHG, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, Buchler MW, Neoptolemos JP, Pancreatic Canc Metaanalysis G (2008) Influence of resection margins and treatment on survival in patients with pancreatic cancer - Meta-analysis of randomized controlled trials. Arch Surg 143(1):75-83PubMedCrossRefGoogle Scholar
  6. Carter R, Stocken DD, Ghaneh P, Bramhall SR, Olah A, Kelemen D, Bassi C, Friess H, Dervenis C, Spry N, Buchler MW, Neoptolemos JP, European Study Grp Pancreatic C (2009) Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data. Int J Cancer 124(12):2960-2965PubMedCrossRefGoogle Scholar
  7. Cress RD, Yin D, Clarke L, Bold R, Holly EA (2006) Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 17(4):403-409PubMedCrossRefGoogle Scholar
  8. Douglass HO Jr (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 59(12):2006-2010Google Scholar
  9. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N, Sargent DJ. 2005. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 138(4), 618-628; discussion 628-630.Google Scholar
  10. Fortner JG, Klimstra DS, Senie RT, Maclean BJ (1996) Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 223(2):147-153PubMedCrossRefGoogle Scholar
  11. Haslam JB, Cavanaugh PJ, Stroup SL (1973) Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer 32(6):1341-1345PubMedCrossRefGoogle Scholar
  12. Kalser MH, Ellenberg SS (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120(8):899-903PubMedCrossRefGoogle Scholar
  13. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. 1999. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230(6), 776-782; discussion 782-774.Google Scholar
  14. Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2(7626):865-867PubMedCrossRefGoogle Scholar
  15. Muller MW, Friess H, Kleeff J, Dahmen R, Wagner M, Hinz U, Breisch-Girbig D, Ceyhan GO, Buchler MW. 2007. Is there still a role for total pancreatectomy? Ann Surg 246(6), 966-974; discussion 974-965.Google Scholar
  16. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Büchler MW (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358(9293):1576-1585PubMedCrossRefGoogle Scholar
  17. Neoptolemos J, Stocken DD, Freiss H, Bassi C, Dunn J, Hickey H, Beger H-G, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler M (2004) A randomised trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12):1200-1210PubMedCrossRefGoogle Scholar
  18. Neoptolemos JP, Stocken DD, Smith CT, Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D, Buchler MW, European Study Grp Pancreatic C (2009a) Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials. Br J Cancer 100(2):246-250PubMedCrossRefGoogle Scholar
  19. Neoptolemos J, Büchler M, Stocken DD, Ghaneh P, Smith D, Bassi C, Moore M, Cunningham D, Dervenis C, Goldstein D. 2009. ESPAC-3(v2) - A multicentre, international, open label, randomised controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. ASCO Abstract LBA4505.Google Scholar
  20. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3):267-277PubMedCrossRefGoogle Scholar
  21. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Kloppel G, Dhaene K, Michelassi F (1998) Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas - A multicenter, prospective, randomized study. Ann Surg 228(4):508-514PubMedCrossRefGoogle Scholar
  22. Riess H, Neuhaus P, Post S, Gellert K, Ridwelski K, Schramm H, Zuelke C, Fahlke J, Langrehr J, Oettle H. 2008. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). In: 33rd European-Society-for-Medical-Oncology Congress Sep 12-16, Stockholm. Oxford Univ Press, Sweden, pp. 45-46Google Scholar
  23. Shaib Y, Davila J, Naumann C, El-Serag H (2007) The impact of curative intent surgery on the survival of pancreatic cancer patients: a US Population-based study. Am J Gastroenterol 102(7):1377-1382PubMedCrossRefGoogle Scholar
  24. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, van Cutsem E, van Dekken H, Klinkenbijl JH, Jeekel J (2007) Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 246(5):734-740PubMedCrossRefGoogle Scholar
  25. Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP (2005) Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 92(8):1372-1381PubMedCrossRefGoogle Scholar
  26. Takada A, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicentre prospective randomised controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95(8):1685-1695PubMedCrossRefGoogle Scholar
  27. Twombly R (2008) Adjuvant chemoradiation for pancreatic cancer: few good data, much debate. J Natl Cancer Inst 100(23):1670-1671PubMedCrossRefGoogle Scholar
  28. Wagner M, Redaelli C, Lietz M, Seiler C, Freiss H, Büchler M (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91:586-594PubMedCrossRefGoogle Scholar
  29. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, Pitt HA, Lillemoe KD, Cameron JL. 1997. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225(5), 621-633; discussion 633-626.Google Scholar
  30. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA, Hruban RH. 2002. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 236(3), 355-366; discussion 366-358.Google Scholar

Copyright information

© Springer-Verlag London Limited 2010

Authors and Affiliations

  • Paula Ghaneh
    • 1
    Email author
  • Khaled Dajani
    • 1
  • Michael G. T. Raraty
    • 1
  • Robert Suttton
    • 1
  • John P. Neoptolemos
    • 1
  1. 1.Division of SurgeryRoyal Liverpool HospitalLiverpoolUK

Personalised recommendations